Market Research Logo

Global Malignant Melanoma Market With Focus on Nevisense System: 2015-2020

Global Malignant Melanoma Market With Focus on Nevisense System: 2015-2020

Scope of the Report

The report titled “Global Malignant Melanoma Market With Focus on Nevisense System: 2015-2020” provides an in-depth analysis of the global malignant melanoma market with detailed analysis of the volume of patients and deaths caused due to melanoma. The report also provides the market size of the global melanoma diagnosis and therapeutics market.

The report provides detailed regional analysis of Americas, Europe, Asia, Oceania and Africa for the malignant melanoma market. Regional analysis includes the melanoma diagnosis and therapeutics market, total volume of melanoma patients and deaths caused by melanoma along with the gender segmentation. The report also includes the country analysis of the U.S. and Australia for malignant melanoma market. It provides the analysis of melanoma patient volume along with the deaths caused.

The report also provides detailed information and analysis on the first objective diagnostic support tool, named, Nevisense system manufactured by SciBase company. This section provides the detailed information about the features and clinical benefits of the device along with the technology of the device and its clinical procedures. This also includes the global and regional analysis of the number of devices sold since its invention, i.e. 2014, its installed base and the competitors.

Furthermore, the report assesses key opportunities in the market and outlines the factors that are and will be driving the growth of the industry. Growth of the overall global melanoma market has also been forecasted for the period 2015-2020, taking into consideration the previous growth patterns, the growth drivers and the current and future trends. The competition in the global melanoma market is stiff and dominated by the big players like Bristol. Further, key players of the melanoma market, Merck and Navidea are also profiled with their financial information and respective business strategies.

Regional Coverage

Europe
Americas
Asia
Oceania
Africa

Country Coverage

United States
Australia

Company Coverage

Bristol-Myers Squibb Company
Merck & Co., Inc.
Navidea Biopharmaceuticals, Inc.

Executive Summary

The global malignant melanoma market is expected to have increased at the significant CAGR during 2012-2015 and projections are made that the market would rise in the next five years i.e. 2016-2020 tremendously. The most affected regions around the world include Americas and Europe followed by Asia, Oceania and Africa. The most common environmental factors resulting in the high prevalence of melanoma include, sun exposure, artificial UV rays and social-economic status of individuals.

The growth drivers for the market are: rise in melanoma cases. Effective immunotherapies and targeted therapy drugs. Despite the market is governed by various growth drivers, there are certain challenges faced by the market such as: lack of awareness among people, high treatment cost and challenges in the developing countries such as insufficient political priorities and funding issues.


1. Executive Summary
2. Introduction
2.1 Introduction to Skin Cancer
2.1.1 Skin Cancer
2.1.2 Types of Skin Cancer
Table 1: Types of Skin Cancer
2.2 Introduction to Malignant Melanoma Skin Cancer
2.2.1 Malignant Melanoma Skin Cancer
2.2.2 Risk Factors of Malignant Melanoma Skin Cancer
2.2.3 Signs and Symptoms of Malignant Melanoma Skin Cancer
2.2.4 Stages of Malignant Melanoma Skin Cancer
2.2.5 Malignant Melanoma Skin Cancer Treatment
Table 2: Malignant Melanoma Skin Cancer Treatments
3. Global Market Analysis
3.1 Global Melanoma Doagnosis and Therapeutics Market Analysis
3.1.1 Global Melanoma Diagnosis and Therapeutics Market by Value
Table 3: Global Melanoma Diagnosis and Therapeutics Market by Value; 2015-2020E (US$ Billion)
3.1.2 Global Melanoma Diagnosis and Therapeutics Market by Region
Table 4: Global Melanoma Diagnnosis and Therapeutics Market by Region; 2015 (%)
3.2 Global Melanoma Market by New Cases Analysis
3.2.1 Global Melanoma Market New Cases by Volume
Table 5: Global Melanoma Market by New Cases; 2012-2020E (Thousand)
Table 5: Global Melanoma Market New Cases by Gender; 2012-2020E (Thousand)
3.2.2 Global Melanoma Market New Cases by Region
Table 7: Global New Cases of Melanoma by Region; 2012-2015E (%)
3.3 Global Melanoma Market by Deaths Caused Analysis
3.3.1 Global Melanoma Market by Deaths Caused (Volume)
Table 8: Global Melanoma Market by Deaths Caused; 2012-2020E (Thousand)
Table 9: Global Melanoma Market by Deaths Caused (Gender Segmentation); 2012-2020E (Thousand)
3.3.2 Global Melanoma Market by Deaths Caused (Regional Analysis)
Table 10: Global Melanoma Market by Deaths Caused (Regional Analysis); 2012-2015E (%)
4. Regional Market Analysis
4.1 Europe Malignant Melanoma Market Analysis
4.1.1 Europe Melanoma Diagnosis and Therapeutics Market by Value
Table 11: Europe Melanoma Diagnosis and Therapeutics Market by Value; 2015-2020E (US$ Million)
4.1.2 Europe Melanoma Market by New Cases
Table 12: Europe Melanoma Market by New Cases; 2012-2020E (Thousand)
Table 13: Europe Melanoma Market New Cases by Gender; 2012-2020E (Thousand)
4.1.3 Europe Melanoma Market by Deaths Caused
Table 14: Europe Melanoma Market by Deaths Caused; 2012-2020E (Thousand)
Table 15: Europe Melanoma Market by Deaths Caused (Gender Segmentation); 2012-2020E (Thousand)
4.2 Americas Malignant Melanoma Market Analysis
4.2.1 Americas Melanoma Market by New Cases
Table 16: Americas Melanoma Market by New Cases; 2012-2020E (Thousand)
Table 17: Americas Melanoma Market New Cases by Gender; 2012-2020E (Thousand)
4.2.2 Americas Melanoma Market by Deaths Caused
Table 18: Americas Melanoma Market by Deaths Caused; 2012-2020E (Thousand)
Table 19: Americas Melanoma Market by Deaths Caused (Gender Segmentation); 2012-2020E (Thousand)
4.2.3 North America Melanoma Diagnosis and Therapeutics Market by Value
Table 20: North America Melanoma Diagnosis and Therapeutics Market by Value; 2015-2020E (US$ Billion)
4.2.4 The U.S. Malignant Melanoma Market Analysis
The U.S. Melanoma Market by New Cases
Table 21: The U.S. Melanoma Market by New Cases; 2012-2020E (Thousand)
Table 22: The U.S. Melanoma Market New Cases by Gender; 2012-2020E (Thousand)
The U.S. Melanoma Market by Deaths Caused
Table 23: The U.S. Melanoma Market by Deaths Caused; 2012-2020E (Thousand)
Table 24: The U.S. Melanoma Market by Deaths Caused (Gender Segmentation); 2012-2020E (Thousand)
4.3 Asia Malignant Melanoma Market Analysis
4.3.1 Asia Melanoma Diagnosis and Therapeutics Market by Value
Table 25: Asia Melanoma Diagnosis and Therapeutics Market by Value; 2015-2020E (US$ Billion)
4.3.2 Asia Melanoma Market by New Cases
Table 26: Asia Melanoma Market by New Cases; 2012-2020E (Thousand)
Table 27: Asia Melanoma Market New Cases by Gender; 2012-2020E (Thousand)
4.3.3 Asia Melanoma Market by Deaths Caused
Table 28: Asia Melanoma Market by Deaths Caused; 2012-2020E (Thousand)
Table 29: Asia Melanoma Market by Deaths Caused (Gender Segmentation); 2012-2020E (Thousand)
4.4 Oceania Malignant Melanoma Market Analysis
4.4.1 Oceania Melanoma Market by New Cases
Table 30: Oceania Melanoma Market by New Cases; 2012-2020E (Thousand)
Table 31: Oceania Melanoma Market New Cases by Gender; 2012-2020E (Thousand)
4.4.2 Oceania Melanoma Market by Deaths Caused
Table 32: Oceania Melanoma Market by Deaths Caused; 2012-2020E (Thousand)
Table 33: Oceania Melanoma Market by Deaths Caused (Gender Segmentation); 2012-2020E (Thousand)
4.4.3 Australia Malignant Melanoma Market Analysis
Australia Melanoma Market by New Cases
Table 34: Australia Melanoma Market by New Cases; 2012-2020E (Thousand)
Table 35: Australia Melanoma Market New Cases by Gender; 2012-2020E (Thousand)
Australia Melanoma Market by Deaths Caused
Table 36: Australia Melanoma Market by Deaths Caused; 2012-2020E (Thousand)
Table 37: Australia Melanoma Market by Deaths Caused (Gender Segmentation); 2012-2020E (Thousand)
4.5 Africa Malignant Melanoma Market Analysis
4.5.1 Africa Melanoma Market by New Cases
Table 38: Africa Melanoma Market by New Cases; 2012-2020E (Thousand)
Table 39: Africa Melanoma Market New Cases by Gender; 2012-2020E (Thousand)
4.5.2 Africa Melanoma Market by Deaths Caused
Table 40: Africa Melanoma Market by Deaths Caused; 2012-2020E (Thousand)
Table 41: Africa Melanoma Market by Deaths Caused (Gender Segmentation); 2012-2020E (Thousand)
5. Melanoma Diagnostic Support Tool: Nevisense
5.1 Introduction to Nevisense
5.1.1 Features of Nevisense
5.1.2 Clinical Benefits of Nevisense
Table 42: Sensitivity Analysis of Nevisense
Table 43: Nevisense Specificity and Sensitivity
5.2 EIS Technology: Nevisense Action Mechanism
5.2.1 EIS Technology
Table 44: EIS Technology of Nevisense
5.2.2 Clinical Procedure
Table 45: Clinical Procedure for Nevisense
5.2.3 EIS Score Explanation
Table 46: EIS Score Explanation for Nevisense
5.3 SciBase Company Profile
5.3.1 SciBase Company Competitors
Table A: SciBase Company Competitors
5.3.2 Nevisense Devices
Table 47: Nevisense Devices Sold by SciBase Company; 2014-2016E (Units)
Table 48: Nevisense Devices Sold by Region; 2014-2020E (Units)
5.4 Nevisense Device Installation Base
Table 49: Nevisense Devices Installation Base; 2014-2016E
6. Market Dynamics
6.1 Growth Drivers
6.1.1 Rise in Melanoma Cases
6.1.2 Effective Immunotherapies
6.1.3 Targeted Therapy Drugs
6.2 Challenges
6.2.1 Lack of Awareness among People
6.2.2 High Cost Associated with the Treatment
6.2.3 Challenges in Developing Countries
6.3 Market Trends
6.3.1 Melanoma Vaccines
6.3.2 Diagnostic Tools
6.3.3 Immunotherapy
6.3.4 Melanoma Genetic Research
7. Competitive Landscape
Table B: Global Malignant Melanoma Market Major Players; 2015
8. Company Profiling
8.1 Bristol-Myers Squibb Company
8.1.1 Business Overview
8.1.2 Financial Overview
Table 50: Bristol Total Revenues; 2011-2015 (US$ Billion)
Table 51: Bristol Revenues by Products; 2015 (%)
Table 52: Bristol Revenues by Region; 2015 (%)
8.1.3 Business Strategy
8.2 Merck & Co., Inc.
8.2.1 Business Overview
8.2.2 Financial Overview
Table 53: Merck & Co. Total Sales; 2011-2015 (US$ Billion)
Table 54: Merck & Co. Sales by Segments; 2015 (%)
Table 55: Merck & Co. Sales by Region; 2015 (%)
8.2.3 Business Strategy
8.3 Navidea Biopharmaceuticals, Inc.
8.3.1 Business Overview
8.3.2 Financial Overview
Table 56: Navidea Total Revenues; 2011-2015 (US$ Million)
8.3.3 Business Strategy

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report